Your browser doesn't support javascript.
loading
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin, Shannon N; Moore, Kathleen; Chon, Hye Sook; Lee, Jung-Yun; Thomes Pepin, Jessica; Sundborg, Michael; Shai, Ayelet; de la Garza, Joseph; Nishio, Shin; Gold, Michael A; Wang, Ke; McIntyre, Kristi; Tillmanns, Todd D; Blank, Stephanie V; Liu, Ji-Hong; McCollum, Michael; Contreras Mejia, Fernando; Nishikawa, Tadaaki; Pennington, Kathryn; Novak, Zoltan; De Melo, Andreia Cristina; Sehouli, Jalid; Klasa-Mazurkiewicz, Dagmara; Papadimitriou, Christos; Gil-Martin, Marta; Brasiuniene, Birute; Donnelly, Conor; Del Rosario, Paula Michelle; Liu, Xiaochun; Van Nieuwenhuysen, Els.
Afiliação
  • Westin SN; University of Texas MD Anderson Cancer Center, Houston, TX.
  • Moore K; Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma, OK.
  • Chon HS; H.Lee Moffitt Cancer Center, Tampa, FL.
  • Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Thomes Pepin J; Minnesota Oncology, Minneapolis, MN.
  • Sundborg M; FirstHealth Moore Regional Hospital, Pinehurst, NC.
  • Shai A; RAMBAM Health Care Campus, Haifa, and Israeli Society of Gynecologic Oncology (ISGO), Israel.
  • de la Garza J; Texas Oncology-San Antonio Medical Center, San Antonio, TX.
  • Nishio S; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
  • Gold MA; Oklahoma Cancer Specialists and Research Institute, Tulsa, OK.
  • Wang K; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • McIntyre K; Texas Health Presbyterian Hospital, Dallas, TX.
  • Tillmanns TD; West Cancer Center Research Institute & University of Tennessee Health Science Center, Memphis, TN.
  • Blank SV; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, and GOG Foundation (GOG-F), USA.
  • Liu JH; Sun Yat-sen University Cancer Center, Guangzhou, China.
  • McCollum M; Virginia Oncology Associates, Brock Cancer Center, Norfolk, VA, and GOG Foundation (GOG-F), USA.
  • Contreras Mejia F; National Cancer Institute of Colombia, Bogotá, Colombia.
  • Nishikawa T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Pennington K; Fred Hutchinson Cancer Center, University of Washington Medical Center, Seattle, WA.
  • Novak Z; National Institute of Oncology, Budapest, and Central and Eastern European Gynecologic Oncology Group (CEEGOG), Hungary.
  • De Melo AC; Clinical Research and Technological Development Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
  • Sehouli J; Charité-Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, and North Eastern German Society of Gynecological Oncology (NOGGO), Germany.
  • Klasa-Mazurkiewicz D; Department of Obstetrics and Gynecology, Gynecological Oncology and Gynecological Endocrinology, Medical University of Gdansk, Gdansk, and Polish Gynecologic Oncology Group (PGOG), Poland.
  • Papadimitriou C; Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, and Hellenic Cooperative Oncology Group (HeCOG), Greece.
  • Gil-Martin M; Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Spain.
  • Brasiuniene B; Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, and Nordic Society of Gynaecological Oncology (NSGO), Lithuania.
  • Donnelly C; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
  • Del Rosario PM; Oncology R&D, Global Medicines Development, AstraZeneca, Cambridge, United Kingdom.
  • Liu X; Oncology R&D, Late-stage Development, AstraZeneca, Gaithersburg, MD.
  • Van Nieuwenhuysen E; University Hospital Leuven, Leuven, and Luxembourg Gynaecological Oncology Group (BGOG), Belgium.
J Clin Oncol ; 42(3): 283-299, 2024 Jan 20.
Article em En | MEDLINE | ID: mdl-37864337
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias do Endométrio / Anticorpos Monoclonais / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias do Endométrio / Anticorpos Monoclonais / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article